Everett Meyer

Everett Meyer MD, PhD, Associate Professor, Department of Medicine, Division of Blood and Marrow Transplantation; Associate Professor, Department of Pediatrics, Division of Stem Cell Transplantation, Associate Professor, (By courtesy), Surgery - Abdominal Transplantation, Stanford University School of Medicine 

Research Description: Dr. Meyer studies immune tolerance for transplanted human islets, achieved by hematopoietic stem cell transplantation. He studies murine pre-clinical models with a focus on T cell immunotherapy, T regulatory cell and invariant NKT cell biology and non-myeloblative hematopoietic stem cell transplantation for tolerance induction. In long-standing collaborations with Dr. Seung Kim, he has developed genetic engineering to reprogram Tregulatory cells which has resulted in startling discoveries: (1) genetically engineered Tregulatory cells producing Chimeric Antigen Receptor (CAR) are much better at preventing islet graft rejection than normal Tregulatory cells and (2) genetically engineered Tregulatory cells can alter the immune system to create new immune memory and tolerance. Those findings stem from studies supported by the Human Islet Resource Network (HIRN) and the JDRF. Dr. Meyer also has expertise in using high throughput sequencing and flow cytometry to monitor T cells responses in patients. He is principal investigator of two phase I or phase I/II clinical trials using T regulatory cells to prevent or treat graft-versus host disease. His laboratory has also begun to compare the antigen presenting cell profile of patients tolerant of their kidney graft to the antigen presenting cell profile from subjects in other groups including normal healthy controls and patients newly diagnosed with Type 1 diabetes. Together with several members of SDRC and Islet Core, Dr. Meyer has established a human islet auto-transplantion program at Stanford (SPIRIT). Dr. Meyer is co-leader of the ‘Immunology, Transplantation and Stem Cells in Diabetes’ Research Affinity Group of SDRC. He is also co-director of the Diabetes Immune Monitoring Core, with Dr. Maecker.

Selected relevant publications (Stanford DRC Members in BOLD):

  1. Iliopoulou BP, Hsu K, Pérez-Cruz M, Tang SW, Pang WW, Erkers T, Kambham N, Freeman GJ, Dekruyff RH, Meyer EH. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation. Blood Adv. 2019 Nov 12;3(21):3419-3431. doi: 10.1182/bloodadvances.2019000286. PMID: 31714958; PMCID: PMC6855109. 

  2. Erkers T, Xie BJ, Kenyon LJ, Smith B, Rieck M, Jensen KP, Ji X, Basina M, Strober S, Negrin RS, Maecker HT, Meyer EH. High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity. Blood. 2020 Mar 12;135(11):814-825. doi: 10.1182/blood.2019001903. PMID: 31935280; PMCID: PMC7068034. [Cites P30] 

  3. Busque S, Scandling JD, Lowsky R, Shizuru J,… Engleman EG, Meyer E, Strober S. Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Sci Transl Med. 2020 Jan 29;12(528):eaax8863. doi: 10.1126/scitranslmed.aax8863. PMID: 31996467. 

  4. Marshall PL, Nagy N, Kaber G, Barlow GL, Ramesh A, Xie BJ, Linde MH, Haddock NL, Lester CA, Tran QL, de Vries CR, Hargil A, Malkovskiy AV, Gurevich I, Martinez HA, Kuipers HF, Yadava K, Zhang X, Evanko SP, Gebe JA, Wang X, Vernon RB, de la Motte C, Wight TN, Engleman EG, Krams SM, Meyer EH, Bollyky PL. Hyaluronan synthesis inhibition impairs antigen presentation and delays transplantation rejection. Matrix Biol. 2021 Feb;96:69-86. doi: 10.1016/j.matbio.2020.12.001. Epub 2020 Dec 5. PMID: 33290836; PMCID: PMC8147171. 

  5. Pathak S, Meyer EH. Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation. Front Immunol. 2021 Jan 29;11:612737. doi: 10.3389/fimmu.2020.612737. PMID: 33658995; PMCID: PMC7917336. 

  6. Zheng P, Tamaresis J, Thangavelu G, Xu L, You X, Blazar BR, Negrin RS, Zehnder JL, Iliopoulou BP, Meyer EH. Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant. Blood Adv. 2020 Sep 8;4(17):4232-4243. doi: 10.1182/bloodadvances.2019000977. PMID: 32898248; PMCID: PMC7479954. 

  7. Meyer EH, Pavlova A, Villar-Prados A, Bader C, Xie B, Muffly L, Kim P, Sutherland K, Bharadwaj S, Dahiya S, Frank M, Arai S, Johnston L, Miklos D, Rezvani A, Shiraz P, Sidana S, Shizuru J, Weng WK, Agrawal V, Putnam A, Fernhoff N, Tamarisis J, Lu Y, Pawar RD, McClellan JS, Lowsky R, Negrin RS. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood. 2025 May 1;145(18):2012-2024. doi: 10.1182/blood.2024026446. PMID: 39792934. 

  8. Mougiakakos D, Meyer EH, Schett G. CAR T cells in autoimmunity: game changer or stepping stone? Blood. 2025 Apr 24;145(17):1841-1849. doi: 10.1182/blood.2024025413. PMID: 39700499. 

  9. Busque S, Scandling JD, Lowsky R, Shizuru J, Jensen K, Waters J, Wu HH, Sheehan K, Shori A, Choi O, Pham T, Fernandez Vina MA, Hoppe R, Tamaresis J, Lavori P, Engleman EG, Meyer E, Strober S. Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Sci Transl Med. 2020 Jan 29;12(528):eaax8863. doi: 10.1126/scitranslmed.aax8863. PMID: 31996467; PMCID: PMC8051148. 

  10. Chen PP, Cepika AM, Agarwal-Hashmi R, Saini G, Uyeda MJ, Louis DM, Cieniewicz B, Narula M, Amaya Hernandez LC, Harre N, Xu L, Thomas BC, Ji X, Shiraz P, Tate KM, Margittai D, Bhatia N, Meyer E, Bertaina A, Davis MM, Bacchetta R, Roncarolo MG. Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Sci Transl Med. 2021 Oct 27;13(617):eabf5264. doi: 10.1126/scitranslmed.abf5264. Epub 2021 Oct 27. PMID: 34705520. 

  11. Jensen KP, Hongo DA, Ji X, Zheng P, Pawar R, Wu TH, Busque S, Scandling JD, Shizuru JA, Lowsky R, Shori A, Dutt S, Waters J, Saraswathula A, Baker J, Tamaresis JS, Lavori P, Negrin R, Maecker H, Engleman EG, Meyer E, Strober S. Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients. Blood Adv. 2021 Sep 14;5(17):3290-3302. doi: 10.1182/bloodadvances.2020003669. PMID: 34432869; PMCID: PMC8525233. 

  12. Chang CA, Bhagchandani P, Poyser J, Velasco BJ, Zhao W, Kwon HS, Meyer E, Shizuru JA, Kim SK. Curative islet and hematopoietic cell transplantation in diabetic mice without toxic bone marrow conditioning. Cell Rep. 2022 Nov 8;41(6):111615. doi: 10.1016/j.celrep.2022.111615. PMID: 36351397. 

  13. Primavera R, Regmi S, Yarani R, Levitte S, Wang J, Ganguly A, Chetty S, Guindani M, Ricordi C, Meyer E, Thakor AS. Precision Delivery of Human Bone Marrow-Derived Mesenchymal Stem Cells Into the Pancreas Via Intra-arterial Injection Prevents the Onset of Diabetes. Stem Cells Transl Med. 2024 Jun 14;13(6):559-571. doi: 10.1093/stcltm/szae020. PMID: 38530131; PMCID: PMC11165159. 

  14. Wu X, Chen PI, Whitener RL, MacDougall MS, Coykendall VMN, Yan H, Kim YB, Harper W, Pathak S, Iliopoulou BP, Hestor A, Saunders DC, Spears E, Sévigny J, Maahs DM, Basina M, Sharp SA, Gloyn AL, Powers AC, Kim SK, Jensen KP, Meyer EH. CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets. Front Immunol. 2024 Jun 28;15:1415102. doi: 10.3389/fimmu.2024.1415102. PMID: 39007132; PMCID: PMC11239501. 

  15. Zaslavsky ME, Craig E, Michuda JK, Sehgal N, Ram-Mohan N, Lee JY, Nguyen KD, Hoh RA, Pham TD, Röltgen K, Lam B, Parsons ES, Macwana SR, DeJager W, Drapeau EM, Roskin KM, Cunningham-Rundles C, Moody MA, Haynes BF, Goldman JD, Heath JR, Chinthrajah RS, Nadeau KC, Pinsky BA, Blish CA, Hensley SE, Jensen K, Meyer E, Balboni I, Utz PJ, Merrill JT, Guthridge JM, James JA, Yang S, Tibshirani R, Kundaje A, Boyd SD. Disease diagnostics using machine learning of B cell and T cell receptor sequences. Science. 2025 Feb 21;387(6736):eadp2407. doi: 10.1126/science.adp2407. Epub 2025 Feb 21. PMID: 39977494; PMCID: PMC12061481.